{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T13:08:24Z","timestamp":1789218504343,"version":"build-2803163510"},"reference-count":69,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["L'Enc\u00e9phale"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.encep.2026.02.008","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T16:33:58Z","timestamp":1775752438000},"page":"519-528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Le LSD revisit\u00e9\u00a0: m\u00e9canismes d\u2019action et potentiel en sant\u00e9 mentale"],"prefix":"10.1016","volume":"52","author":[{"given":"Amel","family":"Bouloufa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Delcourte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Delannay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2161-2204","authenticated-orcid":false,"given":"Nasser","family":"Haddjeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.encep.2026.02.008_bib0350","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMra073096","article-title":"Major depressive disorder","volume":"358","author":"Belmaker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.encep.2026.02.008_bib0355","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/070674370705200108","article-title":"Definition, assessment, and staging of treatment\u2014resistant refractory major depression: a review of current concepts and methods","volume":"52","author":"Berlim","year":"2007","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.encep.2026.02.008_bib0360","first-page":"469680","article-title":"Approaches to understanding and addressing treatment-resistant depression: a scoping review","volume":"2012","author":"Jenkins","year":"2012","journal-title":"Depress Res Treat"},{"key":"10.1016\/j.encep.2026.02.008_bib0365","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1146\/annurev-med-053013-062946","article-title":"Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics","volume":"66","author":"Abdallah","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.encep.2026.02.008_bib0370","doi-asserted-by":"crossref","first-page":"13187","DOI":"10.1038\/s41598-017-13282-7","article-title":"Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms","volume":"7","author":"Carhart-Harris","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.encep.2026.02.008_bib0375","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1523\/JNEUROSCI.1659-20.2020","article-title":"Hallucinogens in mental health: preclinical and clinical studies on LSD, Psilocybin, MDMA, and ketamine","volume":"41","author":"De Gregorio","year":"2021","journal-title":"J Neurosci"},{"key":"10.1016\/j.encep.2026.02.008_bib0380","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/164_2018_107","article-title":"Serotonergic psychedelics: experimental approaches for assessing mechanisms of action","author":"Canal","year":"2018","journal-title":"New Psychoact Subst"},{"key":"10.1016\/j.encep.2026.02.008_bib0385","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pnpbp.2013.04.009","article-title":"Monoamine neurocircuitry in depression and strategies for new treatments","volume":"45","author":"Hamon","year":"2013","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.encep.2026.02.008_bib0390","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/13811110701402587","article-title":"Noradrenergic function in suicide","volume":"11","author":"Pandey","year":"2007","journal-title":"Arch Suicide Res"},{"key":"10.1016\/j.encep.2026.02.008_bib0395","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1038\/s41380-022-01661-0","article-title":"The serotonin theory of depression: a systematic umbrella review of the evidence","volume":"28","author":"Moncrieff","year":"2023","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.encep.2026.02.008_bib0400","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.neuropharm.2016.05.010","article-title":"Ketamine treatment involves medial prefrontal cortex serotonin to induce a rapid antidepressant-like activity in BALB\/cJ mice","volume":"112","author":"Pham","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.encep.2026.02.008_bib0405","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1176\/appi.ajp.161.11.1957","article-title":"Hippocampal volume and depression: a meta-analysis of MRI studies","volume":"161","author":"Videbech","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.encep.2026.02.008_bib0410","doi-asserted-by":"crossref","first-page":"1085950","DOI":"10.3389\/fendo.2023.1085950","article-title":"Understanding the relationships between physiological and psychosocial stress, cortisol and cognition","volume":"14","author":"James","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.encep.2026.02.008_bib0415","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41583-024-00876-0","article-title":"Structural neural plasticity evoked by rapid-acting antidepressant interventions","volume":"26","author":"Liao","year":"2025","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.encep.2026.02.008_bib0420","doi-asserted-by":"crossref","first-page":"107515","DOI":"10.1016\/j.pharmthera.2020.107515","article-title":"Do antidepressants promote neurogenesis in adult hippocampus? A systematic review and meta-analysis on naive rodents","volume":"210","author":"Lino De Oliveira","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.encep.2026.02.008_bib0425","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nri.2015.5","article-title":"The role of inflammation in depression: from evolutionary imperative to modern treatment target","volume":"16","author":"Miller","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.encep.2026.02.008_bib0430","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2174\/1570159X15666171123201142","article-title":"Imaging the role of inflammation in mood and anxiety-related disorders","volume":"16","author":"Felger","year":"2018","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.encep.2026.02.008_bib0435","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/mp.2017.61","article-title":"Neuronal plasticity and neurotrophic factors in drug responses","volume":"22","author":"Castr\u00e9n","year":"2017","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.encep.2026.02.008_bib0440","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1177\/02698811211026426","article-title":"Ketamine's effect on inflammation and kynurenine pathway in depression: a systematic review","volume":"35","author":"Kopra","year":"2021","journal-title":"J Psychopharmacol (Oxf)"},{"key":"10.1016\/j.encep.2026.02.008_bib0445","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/jnc.15536","article-title":"Molecular targets of psychedelic-induced plasticity","volume":"162","author":"Jaster","year":"2022","journal-title":"J Neurochem"},{"key":"10.1016\/j.encep.2026.02.008_bib0450","doi-asserted-by":"crossref","first-page":"118348","DOI":"10.1016\/j.biopha.2025.118348","article-title":"LSD's rapid antidepressant effects are modulated by 5-HT2B receptors","volume":"190","author":"Bouloufa","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.encep.2026.02.008_bib0455","doi-asserted-by":"crossref","first-page":"111278","DOI":"10.1016\/j.pnpbp.2025.111278","article-title":"Psychedelics in neuroinflammation: mechanisms and therapeutic potential","volume":"137","author":"De Deus","year":"2025","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.encep.2026.02.008_bib0460","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/09540261.2018.1481827","article-title":"Psychedelics as anti-inflammatory agents","volume":"30","author":"Flanagan","year":"2018","journal-title":"Int Rev Psychiatry"},{"key":"10.1016\/j.encep.2026.02.008_bib0465","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2416106122","article-title":"Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential","volume":"122","author":"Tuck","year":"2025","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.encep.2026.02.008_bib0470","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s13311-017-0542-y","article-title":"Potential therapeutic effects of psilocybin","volume":"14","author":"Johnson","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.encep.2026.02.008_bib0475","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.brainres.2004.07.044","article-title":"Lysergic acid diethylamide and [\u2013]-2,5-dimethoxy-4-methylamphetamine increase extracellular glutamate in rat prefrontal cortex","volume":"1023","author":"Muschamp","year":"2004","journal-title":"Brain Res"},{"key":"10.1016\/j.encep.2026.02.008_bib0480","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1126\/science.abo3566","article-title":"Design of fast-onset antidepressant by dissociating SERT from nNOS in the DRN","volume":"378","author":"Sun","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.encep.2026.02.008_bib0485","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.euroneuro.2015.12.039","article-title":"The 5-HT1A receptor in major depressive disorder","volume":"26","author":"Kaufman","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.encep.2026.02.008_bib0490","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1176\/appi.ajp.160.1.90","article-title":"Dysfunctional attitudes and 5-HT2\u00a0receptors during depression and self-harm","volume":"160","author":"Meyer","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.encep.2026.02.008_bib0495","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1073\/pnas.1518377113","article-title":"Neural correlates of the LSD experience revealed by multimodal neuroimaging","volume":"113","author":"Carhart-Harris","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.encep.2026.02.008_bib0500","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1038\/s41386-020-0718-8","article-title":"Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin","volume":"45","author":"Mason","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.encep.2026.02.008_bib0505","article-title":"Evidence that 5-HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non-psychedelic drugs","author":"Ippolito","year":"2025","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.encep.2026.02.008_bib0510","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.cell.2016.12.033","article-title":"Crystal structure of an LSD-bound human serotonin receptor","volume":"168","author":"Wacker","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.encep.2026.02.008_bib0515","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41586-024-07403-2","article-title":"Structural pharmacology and therapeutic potential of 5-methoxytryptamines","volume":"630","author":"Warren","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.encep.2026.02.008_bib0520","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.encep.2026.02.008_bib0525","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","article-title":"Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior","volume":"53","author":"Gonz\u00e1lez-Maeso","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.encep.2026.02.008_bib0530","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","article-title":"Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens","volume":"61","author":"Halberstadt","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.encep.2026.02.008_bib0535","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.encep.2026.02.008_bib0540","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1124\/pharmrev.120.000056","article-title":"Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms","volume":"73","author":"Inserra","year":"2021","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.encep.2026.02.008_bib0545","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","article-title":"Psychedelics promote plasticity by directly binding to BDNF receptor TrkB","volume":"26","author":"Moliner","year":"2023","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.encep.2026.02.008_bib0550","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1016\/j.neuron.2025.06.012","article-title":"The polypharmacology of psychedelics reveals multiple targets for potential therapeutics","volume":"113","author":"Jain","year":"2025","journal-title":"Neuron"},{"key":"10.1016\/j.encep.2026.02.008_bib0555","first-page":"8","article-title":"The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs","author":"Carhart-Harris","year":"2014","journal-title":"Front Hum Neurosci"},{"key":"10.1016\/j.encep.2026.02.008_bib0560","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.cub.2016.02.010","article-title":"Increased global functional connectivity correlates with LSD-induced ego dissolution","volume":"26","author":"Tagliazucchi","year":"2016","journal-title":"Curr Biol"},{"key":"10.1016\/j.encep.2026.02.008_bib0565","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1126\/science.adf0435","article-title":"Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors","volume":"379","author":"Vargas","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.encep.2026.02.008_bib0570","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1126\/science.adl0666","article-title":"Isolation of psychedelic-responsive neurons underlying anxiolytic behavioral states","volume":"386","author":"Muir","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.encep.2026.02.008_bib0575","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/jama.2025.13481","article-title":"Single treatment with MM120 (Lysergide) in generalized anxiety disorder: a randomized clinical trial","volume":"334","author":"Robison","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.encep.2026.02.008_bib0580","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials","volume":"26","author":"Krebs","year":"2012","journal-title":"J Psychopharmacol (Oxf)"},{"key":"10.1016\/j.encep.2026.02.008_bib0585","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3389\/fpsyt.2019.00943","article-title":"Therapeutic use of LSD in psychiatry: a systematic review of randomized-controlled clinical trials","volume":"10","author":"Fuentes","year":"2020","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.encep.2026.02.008_bib0590","doi-asserted-by":"crossref","first-page":"636","DOI":"10.2174\/1570159X22666231027111147","article-title":"The psychedelic future of post-traumatic stress disorder treatment","volume":"22","author":"Zaretsky","year":"2024","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.encep.2026.02.008_bib0595","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/14740338.2023.2248883","article-title":"Serotonin 5-HT2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents","volume":"22","author":"McIntyre","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.encep.2026.02.008_bib0600","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1021\/acsptsci.0c00099","article-title":"Low doses of LSD acutely increase BDNF blood plasma levels in healthy volunteers","volume":"4","author":"Hutten","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.encep.2026.02.008_bib0605","first-page":"500","article-title":"Microdosing psychedelics: current evidence from controlled studies","volume":"9","author":"Murphy","year":"2024","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"10.1016\/j.encep.2026.02.008_bib0610","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.biopsych.2019.05.019","article-title":"Acute subjective and behavioral effects of\u00a0microdoses of lysergic acid diethylamide in\u00a0healthy human volunteers","volume":"86","author":"Bershad","year":"2019","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.encep.2026.02.008_bib0615","first-page":"499","article-title":"Clinical research on lysergic acid diethylamide (LSD) in psychiatry and neuroscience","volume":"18","author":"Omidian","year":"2025","journal-title":"Pharm Basel Switz"},{"key":"10.1016\/j.encep.2026.02.008_bib0620","doi-asserted-by":"crossref","first-page":"110762","DOI":"10.1016\/j.neuropharm.2025.110762","article-title":"LSD microdosing in major depressive disorder: results from an open-label trial","volume":"283","author":"Daldegan-Bueno","year":"2026","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.encep.2026.02.008_bib0625","doi-asserted-by":"crossref","first-page":"100725","DOI":"10.1016\/j.medj.2025.100725","article-title":"Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: a randomized trial","volume":"6","author":"M\u00fcller","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.encep.2026.02.008_bib0630","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1186\/s13063-024-08384-3","article-title":"LSDDEP2: study protocol for a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorder","volume":"25","author":"Daldegan-Bueno","year":"2024","journal-title":"Trials"},{"key":"10.1016\/j.encep.2026.02.008_bib0635","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40263-024-01101-3","article-title":"Current perspectives on the clinical research and medicalization of psychedelic drugs for addiction treatments: safety, efficacy, limitations and challenges","volume":"38","author":"Gomez-Escolar","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.encep.2026.02.008_bib0640","series-title":"LSD: My problem child","author":"Hofmann","year":"1980"},{"key":"10.1016\/j.encep.2026.02.008_bib0645","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1017\/S0033291715002901","article-title":"The paradoxical psychological effects of lysergic acid diethylamide (LSD)","volume":"46","author":"Carhart-Harris","year":"2016","journal-title":"Psychol Med"},{"key":"10.1016\/j.encep.2026.02.008_bib0650","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0269881114555249","article-title":"LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects","volume":"29","author":"Gasser","year":"2015","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"10.1016\/j.encep.2026.02.008_bib0655","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.encep.2026.02.008_bib0660","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/brainsci8030047","article-title":"Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives","volume":"8","author":"Martinotti","year":"2018","journal-title":"Brain Sci"},{"key":"10.1016\/j.encep.2026.02.008_bib0665","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0166-4328(96)00102-7","article-title":"Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium","volume":"73","author":"Bonson","year":"1996","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.encep.2026.02.008_bib0670","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/dta.1692","article-title":"Cannabinoid findings in children hair-what do they really tell us? An assessment in the light of three different analytical methods with focus on interpretation of \u03949-tetrahydrocannabinolic acid A concentrations","volume":"7","author":"Moosmann","year":"2015","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.encep.2026.02.008_bib0675","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jamapsychiatry.2023.3867","article-title":"Use of lysergic acid diethylamide by major depression status","volume":"81","author":"Walsh","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.encep.2026.02.008_bib0680","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamapsychiatry.2020.2171","article-title":"The current status of psychedelics in psychiatry","volume":"78","author":"Nutt","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.encep.2026.02.008_bib0685","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","article-title":"A non-hallucinogenic psychedelic analog with therapeutic potential","volume":"589","author":"Cameron","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.encep.2026.02.008_bib0690","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2022489118","article-title":"Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice","volume":"118","author":"Hesselgrave","year":"2021","journal-title":"Proc Natl Acad Sci"}],"container-title":["L'Enc\u00e9phale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700626000588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700626000588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T13:00:52Z","timestamp":1789218052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0013700626000588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":69,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0013700626000588"],"URL":"https:\/\/doi.org\/10.1016\/j.encep.2026.02.008","relation":{},"ISSN":["0013-7006"],"issn-type":[{"value":"0013-7006","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Le LSD revisit\u00e9\u00a0: m\u00e9canismes d\u2019action et potentiel en sant\u00e9 mentale","name":"articletitle","label":"Article Title"},{"value":"L'Enc\u00e9phale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.encep.2026.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 L'Enc\u00e9phale, Paris.","name":"copyright","label":"Copyright"}]}}